Hellenic Society Of Hematology

Research activity is concentrated in newly diagnosed multiple myeloma, relapsed/refractory multiple myeloma, and first-line treatment settings, with additional interest in patients who have received prior lenalidomide- and proteasome inhibitor-based therapy. Studies also address transplant-ineligible disease and treatment sequencing across early and later lines of care.

• Newly diagnosed multiple myeloma
• Relapsed/refractory multiple myeloma
• Transplant-ineligible patients
• Lenalidomide-refractory disease

Several trials focus on antibody-based and combination approaches in myeloma care, including settings with severe renal impairment and treatment-naïve patients requiring tailored therapeutic options.